Physician profile
Lei Zhang
NPI 1821149659
$8,284.14
in general payments reported to CMS, 2019-2025
64 companies · $582 in 2025
The $582 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,516 · 2020: $1,064 · 2021: $1,384 · 2022: $1,492 · 2023: $1,308 · 2024: $939 · 2025: $582.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,828.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,828.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $833.46 | 2021-2025 | Ubrelvy |
| Biogen, INC. | $639.75 | 2019-2025 | Vumerity, Tysabri |
| Novartis Pharmaceuticals Corporation | $634.05 | 2019-2025 | |
| Supernus Pharmaceuticals, INC. | $590.44 | 2019-2025 | Qelbree, Qelbree |
| Corium, LLC | $558.78 | 2022-2025 | Azstarys, Adlarity |
| Ucb, INC. | $436.15 | 2019-2025 | Briviact, Fintepla |
| Sunovion Pharmaceuticals INC. | $389.36 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $303.50 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $269.92 | 2019-2023 | Austedo, Austedo Xr |
| Tris Pharma INC | $241.29 | 2022-2024 | Dyanavel Xr, Onyda Xr |
| Eisai INC. | $217.17 | 2019-2023 | |
| Celgene Corporation | $186.97 | 2021-2023 | Zeposia |
| Jazz Pharmaceuticals INC. | $179.30 | 2019-2025 | |
| Amgen INC. | $167.74 | 2019-2024 | Uplizna |
| Sk Life Science, INC. | $164.46 | 2021-2024 |
Show all 64 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lei Zhang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.